Status:
TERMINATED
Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy
Lead Sponsor:
Pfizer
Conditions:
Endocrine System Diseases
Eligibility:
All Genders
11-17 years
Phase:
PHASE3
Brief Summary
* To assess the effect of a long-term treatment by Genotonorm on linear growth in children with short stature receiving steroid therapy * To assess the effect of a long term treatment with Genotonorm ...
Detailed Description
This trial terminated on 10-Jun-2011 due to prolonged issues with drug accountability and data collection discrepancies. The decision to terminate was not based on any safety concerns.
Eligibility Criteria
Inclusion
- Children with juvenile arthritis or nephrotic syndrome
- Before or during puberty
Exclusion
- Diabetes Type 1 and 2
- Endocrine disease, except well substituted hypothyroidism
Key Trial Info
Start Date :
September 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00174187
Start Date
September 1 2000
End Date
September 1 2011
Last Update
December 4 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Paris, France, 75019
2
Pfizer Investigational Site
Paris, France, 75743